IXensor

iXensor operates at the intersection of mobile technology and medical diagnostics, converting ordinary smartphones into lab-grade analytical devices. The company was established in 2012 after its founding team, Dr. Alan Tsai, Dr. Jerry Chen, and Dr. Carson Chen, met at Stanford University in 2011 and conceived of the core technology. Initially founded in Silicon Valley, the company was later incorporated in Taipei, Taiwan. Dr. Alan Tsai brought over 20 years of experience from the medical device industry, including being a founding member of Bionime. The founders' vision was to leverage the ubiquity of smartphones to reshape healthcare delivery.

The firm's business is centered on its proprietary PixoTech® platform, which utilizes a smartphone's camera and screen lighting to analyze biochemical test strips. This technology, protected by over 80 international patents, enables rapid, quantified results for various biomarkers. iXensor generates revenue through multiple streams: selling its own branded products, technology licensing, co-development partnerships, and Contract Development and Manufacturing Services (CDMO). A strategic partnership and investment from Rohto Pharmaceutical in 2022 aims to digitize Rohto's product lines, particularly in women's health and infectious diseases for the Japanese market.

iXensor's product portfolio targets both at-home self-testing and professional point-of-care diagnostics. A key achievement was securing the world's first FDA approval in 2017 for a smartphone camera-based blood test with its PixoTest® Blood Glucose Monitoring System. The product line has since expanded to address chronic diseases, infectious diseases, and women's health. For chronic conditions like diabetes and cardiovascular disease, the PixoTest POCT system provides rapid, 3-minute tests for HbA1c and lipid panels. In response to the global pandemic, the company launched the CE-marked PixoTest® POCT COVID-19 Antigen Test, an end-to-end digital solution that includes a palm-sized analyzer for objective results, a mobile app for users (PixoHealth Pass), and a HIPAA-grade management portal for organizations. For women's health, the Eveline® brand offers a semi-quantitative ovulation test to aid in fertility planning.

Keywords: mobile health, point-of-care testing, digital diagnostics, PixoTech, smartphone medical devices, in-vitro diagnostics, IVD, at-home self-testing, chronic disease management, infectious disease testing, women's health, fertility tracking, blood glucose monitoring, COVID-19 antigen test, digital health pass, medical technology licensing, CDMO services, telehealth solutions, remote patient monitoring, lab-grade diagnostics